RhumbLine Advisers
SCNI

RhumbLine Advisers’s Scinai Immunotherapeutics SCNI Stock Holding History

RhumbLine Advisers’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42K Buy
1,351
+1,163
+619% +$5.72K ﹤0.01% 3986
2026
Q1 		$1.04K Hold
188
– – ﹤0.01% 3975
2025
Q4 		$1.33K Sell
188
-167
-47% -$1.9K ﹤0.01% 4014
2025
Q3 		$4.49K Buy
355
+7
+2% +$122 ﹤0.01% 3922
2025
Q2 		$7.97K Buy
348
+191
+122% +$4.81K ﹤0.01% 3890
2025
Q1 		$4.17K Sell
157
-8
-5% -$274 ﹤0.01% 3927
2024
Q4 		$5.5K Hold
165
– – ﹤0.01% 3940
2024
Q3 		$5.85K Buy
165
+51
+45% +$1.95K ﹤0.01% 3959
2024
Q2 		$3.24K Buy
114
+47
+70% +$1.95K ﹤0.01% 4148
2024
Q1 		$3.44K Buy
67
+14
+26% +$722 ﹤0.01% 4031
2023
Q4 		$3.08K Buy
53
+18
+51% +$1.24K ﹤0.01% 4050
2023
Q3 		$3.08K Hold
35
– – ﹤0.01% 4060
2023
Q2 		$4.76K Buy
+35
New +$6.04K ﹤0.01% 4097

Other funds holding SCNI

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's SCNI Position: Q2 2026 in Review

RhumbLine Advisers increased its Scinai Immunotherapeutics (SCNI) stake by 619% in Q2 2026, buying an estimated $5.72K and bringing the position to 1,351 shares worth $3.42K. The position accounts for ﹤0.01% of the portfolio, ranked #3986.

RhumbLine Advisers first reported a position in SCNI in Q2 2023 and has held it in 13 quarters since. The position peaked at $7.97K in Q2 2025. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

  • RhumbLine Advisers held 1,351 shares of Scinai Immunotherapeutics worth $3.42K as of Q2 2026.
  • RhumbLine Advisers bought 1,163 Scinai Immunotherapeutics shares in Q2 2026, an estimated $5.72K.
  • Scinai Immunotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3986 holding.
  • RhumbLine Advisers first reported a position in Scinai Immunotherapeutics in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Scinai Immunotherapeutics position peaked at $7.97K in Q2 2025.
  • 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.